Aum Aum
  • About
    • Our Focus
    • Our Leadership
    • Board of Directors
    • Scientific Advisors
  • Our Science
    • Our Approach
    • Pipeline Overview
      • AUM001
      • AUM601
      • AUM302
      • AUM003
    • Publications and Posters
  • Clinical Trials
  • Investors
    • Overview
    • Press Release
    • News Media
    • Events
    • Investor Kit
  • Career
Aum
Press Releases
June 4, 2022
emobitech@gmail.com

AUM Biosciences Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate AUM001 in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer

Continue Reading

Press Releases
June 4, 2022
emobitech@gmail.com

AUM Biosciences Enters into Collaboration with Roche for Clinical Development of AUM001 in Combination with anti-PD-L1 Therapy in Solid Tumor Indications

Continue Reading

Press Releases
June 4, 2022
emobitech@gmail.com

AUM Biosciences Appoints an industry veteran, Scott Jordan as Head of Corporate Development

BETHESDA, Md., May 17, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, today announced the appointment of…

Continue Reading

Singapore office:

10 Anson Rd

#24-16A/B

International Plaza,

Singapore 079903

USA office:

Cullen Building

7265 Wisconsin Avenue

Bethesda,

MD 20814

Australia office:

58 Gipps Street

Collingwood,

Victoria - 3066

China Office:

420, Building 15, Tengfei

Technology Park

No.388 Xinping Street, Suzhou,

Jiangsu, P. R. China - 215000

  • Privacy Policy
  • Terms of Use

Copyright © Aum Bio 2022.

Tel: +65 6808 6034

Fax: +65 6808 6699

Email: info@aumbiosciences.com